The difference between information and
expert, data-driven actionable intelligence
Welcome to the August 2016 issue of CMC Market Outlook
This monthly e-newsletter provides valuable insights for both buyers and sellers of CMC drug development services. Our coverage will help you identify and understand market trends that will inform your strategic business perspective.
Enjoy the August issue!
Slower Bio/Pharma Investment Could Hurt CDMOs in 2017
by Jim Miller, President
Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) may not be feeling it yet, but the downturn in external financing for early stage bio/pharma companies is real. The impact on CDMOs and CROs will be delayed, but there is no doubt that service providers will be feeling it in coming months.
Two recent articles in the financial press underscore what has been happening. An item on Bloomberg.com chronicled the challenges early-stage public companies are facing as they… read on
Vetter to Build US Commercial Facility
Vetter Pharma International will build a 1.2 million-square-foot (112,000-square-meter) commercial injectables manufacturing facility in the US. The company has acquired a 17 acre (7 hectare) site in Des Plaines, Ill., near Chicago’s O’Hare Airport and its clinical manufacturing operation in Skokie.
Vetter plans to spend $320 million over a 10-year period to build out the facility, which is expected to employ 300 people initially and up to 500 at full operation. While no state and local incentives were revealed, it is likely that… read on
Territory Watch: Look Beyond the Usual to Capture New Business
by Katie Ludwick, Marketing Manager
The majority of bio/pharma funding events in the U.S. during 2014 and 2015 occurred outside the high-profile hubs of the San Francisco Bay Area and Boston. However, CROs and CDMOs looking to capture new business will find substantial opportunities in geographically concentrated areas far beyond those more prominent regions.
Business opportunities based on new bio/pharma company financings in geographically compact areas outside the most high-profile venues are truly significant. CROs and CDMOs can strategically focus sales resources in… download now
How big is the market for…?
This is a handy guide to frequently requested data about the bio/pharma contract services industry.
The market for R&D in-house clinical development:
|2015: $26.8 billion||INC Research
Presentation at William Blair 36th Annual Growth Stock Conference
Read more about the size of the contract services market for various segments.
PharmSource Summer Reading: Blog Briefs
As summer winds down, we thought you might be interested in some useful light reading before the autumn craziness begins.
We’ve looked over our blog for some articles we think will be of particular interest to you and your team:
- Global Bio/pharma Continues to Spend on PP&E
- Proposed Saudi Shift Away from Oil May Favor Bio/Pharmaceutical Industry
- Watch Out for the Hangover
We hope you enjoy the rest of your summer and find these articles useful.
PharmSource President Jim Miller to Speak at Industry Event
Contract Pharma: 15th Annual Conference and Tabletop Exhibition.
New Brunswick, New Jersey
Thursday, September 22 at 2:00 pm
Celebrating 20 Years in Business!
Thank you to our clients, colleagues and friends. We look forward to many more years of successful business together.
PharmSource Strategic Advantage
PharmSource’s STRATEGIC ADVANTAGE service is the industry’s most respected outsourcing information web portal for serious consumers of information on contract drug development and manufacturing. Developed from PharmSource’s expert proprietary research, you won’t find this information in any other resource.
See for yourself how this resource gives you vital tools for understanding the industry.
To request a test-drive today, contact Nathaniel Celentano at firstname.lastname@example.org / +1-703-383-4903, ext. 112 (ET USA).